E Ink and Faubel Unveil the Med Label to Revolutionize the Clinical Trial Supply Chain
E Ink® Holdings, "E Ink" (8069.TW), the leading innovator of electronic ink technology and Faubel & Co. Nachf. GmbH, a proven supplier to the pharmaceutical and chemical industry, announced the availability of the Faubel-Med® Label, a smart label for investigational medicinal products. The Med Label features E Ink’s low-voltage film technology, bringing display modules and new system designs to pharmaceutical packaging.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180418005263/en/
The Faubel-Med® Label is a smart label for investigational medicinal products that uses an E Ink display. (Photo: Business Wire)
The Med Label is a combination of an ePaper display and a booklet label that is integrated with radio-frequency identification (RFID) technology to allow pharmaceutical packaging to be updated on demand. The Med Label features a segmented bi-stable E Ink display that can provide expiry updates - even on a sealed kit. This digital solution provides pharmaceutical companies an alternative to relabeling whenever stability data changes, allowing for considerable time and cost savings to international clinical trials.
“The Med Label is a breakthrough product that makes the handling of investigational medicinal products in clinical trial supply chains so much easier,” said Konrad Zachman, Head of Production for New Technologies at Faubel. “As we see a continuous growth in biologic products that require frequent updates on stability data, the Med Label emerges as a cost-effective, highly-efficient smart label that meets the demands of present and future compliance requirements.”
Thanks to E Ink’s ePaper solution, Faubel is expanding its service offerings to provide connected labels with RFID and ePaper technology. Furthermore, this innovation enables the pharmaceutical industry to go digital using valuable tools such as software and real-time reporting, among others. “We believe this is a game changer that will transform clinical trials, saving the industry time and money,” said Frank Jäger, Managing Director at Faubel.
The Med Label is equipped with a battery-free, always-on ePaper display and an RFID tag. It facilitates on-demand label updates for expiry dates at the clinical depot site and provides real time reporting and documentation that meet compliance requirements.
“E Ink’s smart packaging solutions are at the forefront of pharmaceutical packaging innovation,” said Paul Apen, Chief Strategy Officer at E Ink. “Adding displays to pharma packaging requires thin and flexible displays that are also low-power. Our ePaper displays are perfect for this application given their thin, low voltage properties, as well as easy readability, contrast and wide viewing angle.”
E Ink’s new low-voltage film uses roughly 5v compared to the typical 15v driving voltage for electronic paper displays, which decreases the power required for label updates and speeds the update process.
“We are thrilled to partner with Faubel to create a product that will help the pharmaceutical industry take advantage of the digital resources at its disposal,” said FY Gan, Executive Vice President of Sales Center at E Ink. “The potential to enhance and simplify clinical trials is endless; we’re excited to collaborate with industry leaders like Faubel to provide system integration capability for not only the pharmaceutical industry in a total solution, but a wide range of smart packaging applications that deliver the best customer experience of using e-paper for digital transformation.”
The Med Label is currently available for commercial use. To learn more about the solution, visit: http://www.faubel.de/en/pharma-services/clinical-trials/med-label.html.
The Faubel Group is a global supplier of functional labels with various locations in Europe, the USA and Asia. The Faubel Pharma Services business unit has positioned itself as an innovation and quality leader in clinical trial labeling for multinational trials.
Faubel Pharma Services deals with label design, the production of labels of up to 113 pages, the overprinting of pre-produced bulk goods with variable data as well as with routing. In addition to these established services, the multi-service provider develops individual packaging concepts that are able to mask investigational medicinal products and to withstand temperatures down to -196°C.
With its Faubel-Med® Label, the company offers a unique label whose contents can be updated digitally. When stability data changes, the Med Label replaces re-labeling and provides the necessary flexibility for study pooling.
About E Ink Holdings
E Ink Holdings Inc. (8069.TWO), based on technology from MIT’s Media Lab, has transformed and defined the eReader market and is redefining the signage, architecture and design, mobile, wearable and retail markets with its ePaper technology, enabling a new multi-billion dollar market in less than 10 years. Its corporate philosophy aims to deliver revolutionary products, user experiences and environmental benefits through advanced technology development. This vision has led to its continuous investments in the field of ePaper displays as well as expanding the use of its technologies into a number of other markets and applications including smart packaging and fashion. Its Electrophoretic Display products make it the worldwide leader for ePaper. Its Fringe Field Switching (FFS) technologies are a standard for high-end LCD displays and have been licensed to all major liquid crystal display makers in the world. Listed in Taiwan's Taipei Exchange (TPEx) and the Luxembourg market, E Ink Holdings is now the world's largest supplier of ePaper displays. For more information please visit www.eink.com.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Bella Hadid Headlines True Religion’s Latest Campaign20.8.2018 12:32 | Pressemelding
True Religion has tapped Bella Hadid to be the face of the brand. The supermodel embodies all things True Religion, past, present and future; iconic, edgy and everlasting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180820005283/en/ Bella Hadid Headlines True Religion’s Latest Campaign (Photo: Business Wire) An inherit fan of the brand, Bella was the natural choice to meld the iconic essence of the brand with the modern view of its future. An all-star team was assembled including photographer Boo George, stylist Mimi Cuttrell, and hair and makeup duo Jen Atkin and Mary Phillips to create imagery and complementary looks that usher True Religion into a new era that honors the heritage of the brand. A quintessential, confident LA girl with roots at home and abroad, Bella’s voice was not only an inspiration, but an integral part in imagining this campaign, envisioning the brand through her eyes for the next generation of True
Veristat Congratulates Alnylam on the FDA Approval of ONPATTRO™ (patisiran)20.8.2018 11:30 | Pressemelding
Veristat, a full service Clinical Research Organization (CRO), congratulates Alnylam on the recent FDA approval of ONPATTRO™ (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. “On behalf of the entire Veristat team that has supported Alnylam in the development of this therapy, we are humbled to have contributed towards this first-in-class drug approval for Alnylam, for the patients with hATTR amyloidosis and their families,” said John P. Balser, Ph.D., President and Co-Founder of Veristat. “We are continuing to support Alnylam as they look to expand regulatory approval of this treatment to other regions of the world.” Veristat began working with Alnylam over 11 years ago and helped design the studies and prepare the Investigational New Drug (IND) submission for patisiran. Our collaboration continued throughout the entire patisiran program inclusive of a phase 2 study, a phase 3 pivotal study
FRISS Brings Claim Fraud Analysis to a Next Level With Web-IQ´s Innovative Online Network Solution20.8.2018 11:30 | Pressemelding
Asking your neighbor or friend to sign as a witness to a claim for car damages at your insurance company will work no more, with the new Claim Fraud Analysis feature of FRISS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180820005039/en/ Eldert van Wijngaarden (Web-IQ) and Philip van Waning (FRISS) shaking hands. (Photo: Business Wire) FRISS, the worldwide provider of AI powered fraud and risk solutions for the P&C insurance industry, recently added a new and innovative feature in their fraud analytics solution: Online Network Analysis from Web-IQ. This feature automatically identifies if the claimants and the insured or other involved persons are related to each other in an on-line environment. This is a proven and strong indicator for fraudulent claims. Especially with car accidents and other types of claims where multiple persons are involved, it adds a whole new approach to the traditional claim analyses. “Research sho
Global IBC Future Zone and IABM Future Trends Theatre to Explore the Latest Tech Shaping the Industry20.8.2018 11:18 | Pressemelding
IBC2018, the world’s most influential media, entertainment and technology show, today announces the line-up for the IBC Future Zone and IABM Future Trends Theatre. Well established as part of the IBC Exhibition, from 14-18 September, the Future Zone brings together the very latest ideas, innovations and concept technologies from international industry and academia and showcases them in a single specially-curated area sitting alongside exhibition Hall 8. This year, the focus is on showing how new technologies grow from their first inception and progress through to research, development, and validation projects; right through to maturing into the ground-breaking applications and future product standards. Major industry trail-blazers presenting their visions of the future, include Japan’s NHK and BBC R&D from the UK. Both companies will demonstrate a number of technology advances, including: Web-VR applications; object-based media scenarios; pathways to 8K resolution for UHD; and Artifici
Ocean Ambassador of the Netherlands Joins Endowment for Clean Ocean’s Entrepreneur Judges Committee20.8.2018 11:07 | Pressemelding
The Endowment for Clean Oceans (ECO) announced Willemijn Peeters, Ocean Ambassador of the Netherlands and the Founding Director of Searious Business has joined ECO’s Entrepreneur Committee that will vet contestants’ plans to remove macro and micro plastics from the world’s oceans. “I am working to solve the problem of what to do with the plastic once it is removed from the ocean, by helping to create a market for plastic recovered from the ocean,” said Peeters. “Just like we need to end the use of single use plastic, we need to replace the manufacture of virgin plastic and replace it with recycled plastics, and as much as possible needs to be plastic recovered from the ocean.” View source version on businesswire.com: https://www.businesswire.com/news/home/20180820005004/en/ Contact information The Endowment for Clean Oceans Daniel Perrin Daniel.Perrin@endowmentforcleanoceans.org or firstname.lastname@example.org
HeartSciences Showcases MyoVista® Wavelet ECG at 2018 European Society of Cardiology Congress (ESC)20.8.2018 11:00 | Pressemelding
HeartSciences, a medical device company developing next generation ECG devices using continuous wavelet transform (CWT) signal processing and artificial intelligence, is proud to announce its participation as an exhibitor at the upcoming 2018 European Society of Cardiology Congress (ESC). The Congress will take place at Messe Munich International in Munich, Germany and will run from August 25 to August 29, 2018. HeartSciences will highlight its MyoVista® Wavelet ECG (wavECG™) Cardiac Testing Device as well as recent clinical study results published in the Journal of the American College of Cardiology (JACC) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180820005047/en/ MyoVista Wavelet ECG 12-Lead Cardiac Testing Device (Photo: Business Wire) The JACC article titled “Prediction of Abnormal Myocardial Relaxation from Signal Processed Surface ECG” presented the results from the investigator-initiated clinical study that focus